On Monday, Shares of Broadcom Corporation (NASDAQ:BRCM), lost -1.12% to $53.19.
Broadcom Corporation, declared general availability of Broad View software, the industry’s first and most scalable instrumentation suite for monitoring switch performance. Designed to take advantage of advanced features in the Broadcom Strata XGS Trident and Tomahawk™ network switch platforms, Broad View instrumentation software delivers smarter network analytics, enabling operators to optimize network performance across diverse hardware platforms and network operating systems. For more news, visit Broadcom’s Newsroom.
In modern mega-scale data center networks, operators monitor large arrays of switch devices to generate a unified view of network performance. With Broad View software, network operators can now leverage an open standard software interface to extract network instrumentation and telemetry data in a consistent manner across multiple vendor platforms. By using a platform-agnostic application programming interface (API) and leveraging open-source reference controller implementations, operators gain deeper visibility into their cloud networks while protecting their investment in existing applications and getting to market faster.
“The rapid innovations in software-defined networking (SDN) instrumentation call for a standardized interface to the switches that comprise the network,” said Nick Kucharewski, Broadcom Vice President, Network Switch Marketing. “With an open standard API supported on the most pervasive switch silicon portfolio, Broadcom has established a platform that will enable an open ecosystem of network visibility applications running on a wide range of network equipment.”
Broadcom Corporation provides semiconductor solutions for wired and wireless communications. Its products offer voice, video, data, and multimedia connectivity in the home, office, and mobile environments. The company operates in two segments: Broadband and Connectivity, and Infrastructure and Networking.
Shares of SouFun Holdings Ltd (NYSE:SFUN), declined -3.67% to $7.09, during its last trading session.
SouFun Holdings Limited, will report its unaudited third quarter 2015 financial results before the U.S. market opens on Wednesday, November 18, 2015.
SouFun Holdings Limited operates a real estate Internet portal, and home furnishing and improvement Websites in the People’s Republic of China. The company offers marketing services on its Websites, primarily through advertisements to real estate developers in the marketing phase of new property developments, in addition to to real estate agencies; and suppliers of home furnishing and improvement, and other home-related products and services.
Finally, Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), ended its last trade with 3.28% gain, and closed at $10.38.
Achillion Pharmaceuticals, declared that a presented abstract has been accepted for oral presentation at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL, December 5 – 8, and for inclusion in the 2016 Highlights of ASH. The abstract entitled, “Small Molecule Factor D Inhibitors Block Complement Activation in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome,” details research conducted by Dr. Robert Brodsky and his team at Johns Hopkins University School of Medicine, with highly potent and specific factor D inhibitors from Achillion’s complement inhibitor platform.
Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, commented, “The alternative pathway within the complement system plays a noteworthy role in multiple serious and underserved diseases. This research conducted by Dr. Brodsky and his associates demonstrates that Achillion’s compounds effectively block the breakdown of PNH cells and mitigate the accumulation of C3 fragments on cells which leads to extravascular hemolysis. Furthermore, the effect observed with these inhibitors for aHUS was observed in the first reliable human, in vitro model of the disease, which was developed by Dr. Brodsky and his colleagues.”
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.